Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Theodore Karrison

Showing results (31-40 of 155) with videos related to

Pageof 16
Sort By:
European Urology|March 14, 2009
A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancerRussell Szmulewitz, Supriya Mohile, Edwin Posadas, et al.
Blood|November 23, 2013
Cell intrinsic and extrinsic factors synergize in mice with haploinsufficiency for Tp53, and two human del(5q) genes, Egr1 and ApcAngela Stoddart, Jianghong Wang, Anthony A Fernald, et al.
Journal of Surgical Oncology|October 22, 2015
Increased utilization of postmastectomy radiotherapy in the United States from 2003 to 2011 in patients with one to three tumor positive nodesKatharine Yao, Erik Liederbach, Waseem Lutfi, et al.
Investigational New Drugs|May 4, 2004
9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortiumHedy L Kindler, Anjali Avadhani, Kurombi Wade-Oliver, et al.
Annals of Surgery|September 23, 2003
Long-term functional results after ileal pouch anal restorative proctocolectomy for ulcerative colitis: a prospective observational studyFabrizio Michelassi, John Lee, Michele Rubin, et al.
Health Affairs (Project Hope)|May 16, 2009
What does it cost physician practices to interact with health insurance plans?Lawrence P Casalino, Sean Nicholson, David N Gans, et al.
JCO Global Oncology|July 7, 2020
ARETTA: Assessing Response to Neoadjuvant Taxotere and Subcutaneous Trastuzumab in Nigerian Women With HER2-Positive Breast Cancer: A Study ProtocolAtara I Ntekim, Abiola Ibraheem, Adenike A Sofoluwe, et al.
American Journal of Clinical Oncology|April 17, 2010
A phase II trial of gemcitabine, capecitabine, and bevacizumab in metastatic renal carcinomaElizabeth K Chung, Edwin M Posadas, Kristen Kasza, et al.
Blood Cancer Journal|October 7, 2024
Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)Benjamin A Derman, Ajay Major, Jennifer Cooperrider, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2002
Determination of the optimal modulatory dose of O6-benzylguanine in patients with surgically resectable tumorsM Eileen Dolan, Mitchell Posner, Theodore Karrison, et al.
Pageof 16

Showing results (31-40 of 155) with videos related to

Sort By:
Pageof 16
European Urology|March 14, 2009
A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancerRussell Szmulewitz, Supriya Mohile, Edwin Posadas, et al.
Blood|November 23, 2013
Cell intrinsic and extrinsic factors synergize in mice with haploinsufficiency for Tp53, and two human del(5q) genes, Egr1 and ApcAngela Stoddart, Jianghong Wang, Anthony A Fernald, et al.
Journal of Surgical Oncology|October 22, 2015
Increased utilization of postmastectomy radiotherapy in the United States from 2003 to 2011 in patients with one to three tumor positive nodesKatharine Yao, Erik Liederbach, Waseem Lutfi, et al.
Investigational New Drugs|May 4, 2004
9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortiumHedy L Kindler, Anjali Avadhani, Kurombi Wade-Oliver, et al.
Annals of Surgery|September 23, 2003
Long-term functional results after ileal pouch anal restorative proctocolectomy for ulcerative colitis: a prospective observational studyFabrizio Michelassi, John Lee, Michele Rubin, et al.
Health Affairs (Project Hope)|May 16, 2009
What does it cost physician practices to interact with health insurance plans?Lawrence P Casalino, Sean Nicholson, David N Gans, et al.
JCO Global Oncology|July 7, 2020
ARETTA: Assessing Response to Neoadjuvant Taxotere and Subcutaneous Trastuzumab in Nigerian Women With HER2-Positive Breast Cancer: A Study ProtocolAtara I Ntekim, Abiola Ibraheem, Adenike A Sofoluwe, et al.
American Journal of Clinical Oncology|April 17, 2010
A phase II trial of gemcitabine, capecitabine, and bevacizumab in metastatic renal carcinomaElizabeth K Chung, Edwin M Posadas, Kristen Kasza, et al.
Blood Cancer Journal|October 7, 2024
Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)Benjamin A Derman, Ajay Major, Jennifer Cooperrider, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2002
Determination of the optimal modulatory dose of O6-benzylguanine in patients with surgically resectable tumorsM Eileen Dolan, Mitchell Posner, Theodore Karrison, et al.
Pageof 16